William I Bensinger

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. ncbi request reprint Safety of granulocyte colony-stimulating factor in normal donors
    F Gutierrez-Delgado
    Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, Washington 98109, USA
    Curr Opin Hematol 8:155-60. 2001
  2. ncbi request reprint Allogeneic hematopoietic cell transplantation for multiple myeloma
    W I Bensinger
    University of Washington, The Fred Hutchinson Cancer Research Center, Seattle 98109, USA
    Biomed Pharmacother 56:133-8. 2002
  3. doi request reprint Allogeneic stem cell transplantation for multiple myeloma
    William Bensinger
    Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D5 390, Seattle, WA 98109, USA Electronic address
    Hematol Oncol Clin North Am 28:891-902. 2014
  4. pmc Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
    Mohamed A Kharfan-Dabaja
    Blood and Marrow Transplantation Program, H Lee Moffitt Cancer Center University of South Florida College of Medicine, Tampa, FL, USA
    J Hematol Oncol 6:2. 2013
  5. pmc Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center
    W Bensinger
    University of Washington and the Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Bone Marrow Transplant 47:1312-7. 2012
  6. doi request reprint A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma
    William Bensinger
    Clinical Research Division, Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA 98109 1024, USA
    Br J Haematol 159:58-66. 2012
  7. pmc Allogeneic transplantation: peripheral blood vs. bone marrow
    William I Bensinger
    Division of Clinical Research, The Fred Hutchinson Cancer Research Center and Department of Medicine, University of Washington, Seattle, Washington, USA
    Curr Opin Oncol 24:191-6. 2012
  8. ncbi request reprint The current status of hematopoietic stem cell transplantation for multiple myeloma
    William I Bensinger
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Clin Adv Hematol Oncol 2:46-52. 2004
  9. doi request reprint Improving stem cell mobilization strategies: future directions
    W Bensinger
    Department of Medicine, Division of Oncology, University of Washington School of Medicine, Seattle, WA, USA
    Bone Marrow Transplant 43:181-95. 2009
  10. pmc Is there still a role for allogeneic stem-cell transplantation in multiple myeloma?
    William I Bensinger
    University of Washington, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D5 390, Seattle, WA 98109, USA
    Best Pract Res Clin Haematol 20:783-95. 2007

Detail Information

Publications42

  1. ncbi request reprint Safety of granulocyte colony-stimulating factor in normal donors
    F Gutierrez-Delgado
    Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, Washington 98109, USA
    Curr Opin Hematol 8:155-60. 2001
    ..Although the administration of G-CSF to normal donors for PBSC collection appears safe, longer follow-up is required...
  2. ncbi request reprint Allogeneic hematopoietic cell transplantation for multiple myeloma
    W I Bensinger
    University of Washington, The Fred Hutchinson Cancer Research Center, Seattle 98109, USA
    Biomed Pharmacother 56:133-8. 2002
    ..Further follow-up and randomized trials will help to define the utility of this strategy...
  3. doi request reprint Allogeneic stem cell transplantation for multiple myeloma
    William Bensinger
    Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D5 390, Seattle, WA 98109, USA Electronic address
    Hematol Oncol Clin North Am 28:891-902. 2014
    ..These approaches include vaccines, monoclonal antibodies, and adoptive immunotherapies. ..
  4. pmc Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
    Mohamed A Kharfan-Dabaja
    Blood and Marrow Transplantation Program, H Lee Moffitt Cancer Center University of South Florida College of Medicine, Tampa, FL, USA
    J Hematol Oncol 6:2. 2013
    ..A previously published meta-analysis has been reported; however, it suffers from serious methodological flaws...
  5. pmc Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center
    W Bensinger
    University of Washington and the Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Bone Marrow Transplant 47:1312-7. 2012
    ..0. Transplant mortality was reduced and only influenced by a prior tandem autograft...
  6. doi request reprint A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma
    William Bensinger
    Clinical Research Division, Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA 98109 1024, USA
    Br J Haematol 159:58-66. 2012
    ..These findings indicate that single-agent lucatumumab was well tolerated up to 4·5 mg/kg with modest clinical activity in relapsed/refractory MM, warranting further study as a combination therapy...
  7. pmc Allogeneic transplantation: peripheral blood vs. bone marrow
    William I Bensinger
    Division of Clinical Research, The Fred Hutchinson Cancer Research Center and Department of Medicine, University of Washington, Seattle, Washington, USA
    Curr Opin Oncol 24:191-6. 2012
    ..Peripheral blood stem cells (PBSCs) have been widely adopted as a source of stem cells for allogeneic transplantation, although controversy remains regarding their role compared to the use of bone marrow...
  8. ncbi request reprint The current status of hematopoietic stem cell transplantation for multiple myeloma
    William I Bensinger
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Clin Adv Hematol Oncol 2:46-52. 2004
    ....
  9. doi request reprint Improving stem cell mobilization strategies: future directions
    W Bensinger
    Department of Medicine, Division of Oncology, University of Washington School of Medicine, Seattle, WA, USA
    Bone Marrow Transplant 43:181-95. 2009
    ..Novel agents used in conjunction with cytokines have the potential to increase PBSC collections without introducing additional morbidity, thereby improving patient outcomes...
  10. pmc Is there still a role for allogeneic stem-cell transplantation in multiple myeloma?
    William I Bensinger
    University of Washington, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D5 390, Seattle, WA 98109, USA
    Best Pract Res Clin Haematol 20:783-95. 2007
    ....
  11. ncbi request reprint Stem-cell transplantation for multiple myeloma in the era of novel drugs
    William Bensinger
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Clin Oncol 26:480-92. 2008
    ....
  12. ncbi request reprint Initial Therapy of Multiple Myeloma in Patients who are Candidates for Stem Cell Transplantation
    William Bensinger
    Fred Hutchinson Cancer Research Center, D5 390 1100 Fairview Avenue N, Seattle, WA 98118, USA
    Curr Treat Options Oncol 8:135-43. 2007
    ..Thus new regimens incorporating novel agents should improve overall response rates, increase complete responders which should translate into improved progression free and overall survival...
  13. ncbi request reprint Reduced intensity allogeneic stem cell transplantation in multiple myeloma
    William I Bensinger
    University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Front Biosci 12:4384-92. 2007
    ....
  14. pmc Individual patient data meta-analysis of allogeneic peripheral blood stem cell transplant vs bone marrow transplant in the management of hematological malignancies: indirect assessment of the effect of day 11 methotrexate administration
    W Bensinger
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Bone Marrow Transplant 38:539-46. 2006
    ..We hypothesize that the fourth dose of MTX provides extra immunosuppression among BM recipients resulting in a reduced anti-leukemic effect. This hypothesis can only be proved or disproved by a prospective, randomized trial...
  15. ncbi request reprint The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma
    W I Bensinger
    Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA
    Leukemia 20:1683-9. 2006
    ....
  16. pmc Role of autologous and allogeneic stem cell transplantation in myeloma
    W I Bensinger
    Division of Oncology, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA
    Leukemia 23:442-8. 2009
    ....
  17. ncbi request reprint Dose escalation of busulfan with pentoxifylline and ciprofloxacin in patients with breast cancer undergoing autologous transplants
    William I Bensinger
    Fred Hutchinson Cancer Research Center, and University of Washington School of Medicine Seattle, Wash, USA
    Oncology 67:368-75. 2004
    ....
  18. ncbi request reprint The role of hematopoietic stem cell transplantation in the treatment of multiple myeloma
    William I Bensinger
    University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    J Natl Compr Canc Netw 2:371-8. 2004
    ....
  19. ncbi request reprint Recent developments in hematopoietic stem cell transplantation for multiple myeloma
    William I Bensinger
    University of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Int J Hematol 77:232-8. 2003
    ....
  20. doi request reprint Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma
    William I Bensinger
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109, USA
    Br J Haematol 148:562-8. 2010
    ..Toxicities were predictable and manageable; the most-commonly reported grade 3/4 toxicity was neuropathy (11%). This novel sequential three-drug combination therapy is effective and well-tolerated in previously untreated MM patients...
  21. pmc Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow
    Marco Mielcarek
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 119:2675-8. 2012
    ..In summary, transplantation of HLA-identical related G-PBMCs, compared with marrow, was associated with superior short-term and long-term DFS, and there was no evidence that this benefit was outweighed by GVHD-related late mortality...
  22. ncbi request reprint Factors affecting antibody levels after allogeneic hematopoietic cell transplantation
    Jan Storek
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 101:3319-24. 2003
    ....
  23. pmc High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience
    Ajay K Gopal
    Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington 98195, USA
    Cancer 113:1344-50. 2008
    ..We explored the utility of HDT and ASCT for chemoresistant HL because there are few established therapies for these patients...
  24. pmc Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission
    Andrew J Cowan
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington
    Biol Blood Marrow Transplant 22:380-5. 2016
    ..38 years (HR, 3.69; P = .002). MRD positivity is independently associated with poor outcomes after ASCT for MCL patients in CR. ..
  25. pmc Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation
    Ryan D Cassaday
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Biol Blood Marrow Transplant 19:1403-6. 2013
    ..These factors also independently predicted overall survival. In summary, we have defined 3 simple factors that can identify patients with relapsed/refractory MCL who derive a durable benefit from salvage auto HCT...
  26. ncbi request reprint Modified total body irradiation as a planned second high-dose therapy with stem cell infusion for patients with bone-based malignancies
    Renata E Zaucha
    Fred Hutchinson Cancer Research Center, University of Washington, Clinical Research Division, Seattle, WA 98109 1024, USA
    Int J Radiat Oncol Biol Phys 64:227-34. 2006
    ....
  27. pmc Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation
    Lihua E Budde
    825 Eastlake Ave E, G3 200, Seattle, WA, USA
    J Clin Oncol 29:3023-9. 2011
    ....
  28. pmc Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma
    Solomon A Graf
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington Department of Medicine, University of Washington, Seattle, Washington Veterans Affairs Puget Sound Health Care System, Seattle, Washington
    Biol Blood Marrow Transplant 22:1582-7. 2016
    ..Whether AUD indicates additional organ dysfunction or sociobehavioral abnormality warrants further investigation. The composite model may improve risk stratification before autologous HCT. ..
  29. pmc The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cells
    Ajay K Gopal
    Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington 98195, USA
    J Clin Apher 27:81-7. 2012
    ..11 × 10(6) /kg (P < 0.03). A real-time rescue use of plerixafor is feasible and may allow targeted use of this agent. J. Clin. Apheresis, 2012. © 2012 Wiley Periodicals, Inc...
  30. pmc High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma
    Ryan D Cassaday
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, USA
    Br J Haematol 171:788-97. 2015
    ..These data support the further study of RIT and radiation-based strategies in a risk-adapted approach to ASCT for persistent MCL. ..
  31. pmc Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity
    Colin Phipps
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Leuk Lymphoma 56:92-6. 2015
    ..11, p = 0.01). Pre-transplant rituximab-sensitivity is a strong independent predictor of post-transplant outcomes in relapsed FL, although one-third of RR patients achieved a PFS of over 3 years with ASCT...
  32. ncbi request reprint Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors
    Kai Hubel
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Transfusion 42:1414-21. 2002
    ....
  33. ncbi request reprint Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial
    Mary E D Flowers
    Division of Clinical Research, Fred Hutchinson Cancer Research Center and Department of Medicine, University of Washington, Seattle, WA 98109, USA
    Blood 100:415-9. 2002
    ..Assessment of the overall benefits of PBSCT compared to BMT will require continued long-term follow up of morbidity associated with chronic GVHD...
  34. ncbi request reprint The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review
    Theresa Hahn
    Roswell Park Cancer Institute, Department of Medicine, Buffalo, New York 14263, USA
    Biol Blood Marrow Transplant 9:4-37. 2003
    ..The priority area of needed future research is maintenance therapy posttransplantation with nothing versus interferon alpha versus other agents such as corticosteroids or thalidomide or its derivatives...
  35. ncbi request reprint Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation
    J Storek
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA
    Blood 97:3380-9. 2001
    ..008). In conclusion, blood stem cell recipients have higher lymphocyte-subset counts and this appears to result in fewer infections. (Blood. 2001;97:3380-3389)..
  36. ncbi request reprint Risk factors for syngeneic graft-versus-host disease after adult hematopoietic cell transplantation
    Kristina M Adams
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Human Immunogenetics Program, 1100 Fairview Ave N, D2 100, PO Box 19024, Seattle, WA 98109 19024, USA
    Blood 104:1894-7. 2004
    ..01). Overall, risk factors were similar to those described in GVHD. Although an independent effect of parity could not be completely separated from other factors, donor and recipient pregnancy history merits further investigation...
  37. doi request reprint A View from the Plateau: Is There a Role for Allogeneic Stem Cell Transplantation in the Era of Highly Effective Therapies for Multiple Myeloma?
    Damian J Green
    Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, 1100 Fairview Ave N MS D3 190, Seattle, WA, 98109, USA
    Curr Hematol Malig Rep . 2017
    ..Moreover, allo-HCT remains the only mechanism through which MM patients are reliably cured and for the high-risk population represent an important treatment option that provides them access to an otherwise elusive survival plateau...
  38. pmc A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies
    Damian J Green
    Authors Affiliations Clinical Research Division, Fred Hutchinson Cancer Research Center Departments of Medicine, Radiation Oncology, and Laboratory Medicine, University of Washington, Seattle and Dade Moeller Health Group, Richland, Washington
    Cancer Res 74:1179-89. 2014
    ....
  39. ncbi request reprint Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen
    F Gutierrez-Delgado
    Fred Hutchinson Cancer Research, Veterans Administration Hospital, University of Washington, Seattle, WA, USA
    Bone Marrow Transplant 32:279-85. 2003
    ..ASCT is an effective treatment for patients with refractory/relapsed HD. Female patients and patients with less advanced disease at transplant had a better outcome. Patients with prior irradiation benefited from the Bu/Mel/T regimen...
  40. ncbi request reprint A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation
    K Lilleby
    Fred Hutchinson Cancer Research Center, the Seattle Cancer Care Alliance and the University of Washington, 1100 Fairview Avenue N, Seattle, WA 98109, USA
    Bone Marrow Transplant 37:1031-5. 2006
    ..Patient-reported pain was significantly lower and activities were significantly better in the cryotherapy group...
  41. ncbi request reprint Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors
    D Hawkins
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Med Pediatr Oncol 34:328-37. 2000
    ..We describe the toxicity and efficacy of a myeloablative chemotherapy regimen, followed by a second myeloablative radiotherapy regimen as consolidation treatment for poor-risk ESFT...
  42. ncbi request reprint Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting
    Patrick J Stiff
    Cardinal Bernardin Cancer Center, Maywood, IL 60153, USA
    J Clin Oncol 24:5186-93. 2006
    ....